MMP2 and migraine disorder: The outcomes included the number of migraine attacks per week, the average duration of attacks, pain intensity assessed with the VAS scale, matrix metalloproteinase‐2 (MMP‐2) activity in serum, and quality of life measured with the SF‐36 questionnaire.